April 1, 2020 Mind Medicine Inc., a New York-based psychedelic drug development company, that counts Shark Tank star Kevin O’Leary and Toms Shoes founder Blake Mycoskie as investors, has acquired the exclusive rights to eight clinical trials
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NEO: MMED) (OTC: MMEDF) has acquired exclusive rights to data, compounds, and patents for research with LSD and other psychedelics from the Liechti laboratory in Switzerland’s UHB.
Mind Medicine (MindMed) Inc. (NEO: MMED; OTCQB: MMEDF) (the "Company" or "MindMed"), the leading psychedelic pharmaceutical company, is pleased to announce that the Company has graduated from the OTC Pink Open Market to the OTCQB Venture Market ("OTCQB").
Neuro-pharmaceutical and psychedelics research company Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) announced Wednesday the inclusion of the psychoactive compound MDMA to its R&D pipeline. The move comes as part of the company’s exclusive collaboration agreement.
Mind Medicine Inc. can lay claim to the most important one thus far. The developer of psychedelic-inspired medicines with two primary pipeline compounds just announced that one of them is being prepared for Phase 2 study.
Once stigmatized across the western world, the likes of MDMA, LSD and magic mushrooms are taking back their place in the world of medicine. Recreational wellness startups have begun to pop up, too. But the industry is crying out for a repositioning.
"It is very clear that psychedelics need to be regulated by the FDA, and I believe MindMed has both the team and strategy to conduct the necessary trials and create next-generation psychedelics.” said MindMed Investor and Board Member Bruce Linton
Investors in the latest round include Kevin O'Leary, Bruce Linton, the former CEO of the world's biggest cannabis grower, Canopy Growth, and James Bailey, a partner at private equity firm Bail Capital and early investor in psychedelics company Compass Pathways.